| HOME >> MEDICINE >> TECHNOLOGY |
AUSTRALIA 111
TABLE 79 CANCER THERAPY SALES, 2008 AND 2018 ($ MILLIONS) 112
TABLE 80 AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018 ($ MILLIONS) 112
BREAST CANCER DRUGS AND INDIA 112
CHINA 113
EUROPE 113
CONCLUSIONS 113
CHAPTER 8 BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET 115
CANCER COSTS PROJECTED TO REACH AT LEAST $158 BILLION IN 2020 115
CANCER DRUG MARKET 115
TABLE 81 ANTINEOPLASTIC MABS MARKET, 2008 AND 2014 ($ MILLIONS) 116
U.S. PERSONALIZED MEDICINE MARKET SIZE 116
TABLE 82 U.S. PERSONALIZED MEDICINE MARKET, THROUGH 2016 ($ MILLIONS) 117
FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2010–2016 ($ MILLIONS) 117
TABLE 83 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES
MARKET, THROUGH 2016 ($ MILLIONS) 118
FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES
MARKET, 2010–2016 ($ MILLIONS) 118
PERSONALIZED MEDICINE AND ISSUES 118
FACTORS INFLUENCING THE MARKET GROWTH AND INDUSTRY SPECIFIC
CHALLENGES 119
TABLE 84 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2016 ($MILLIONS) 119
U.S. MOLECULAR-BASED CANCER TISSUE DIAGNOSTICS 119
IN VITRO DIAGNOSTICS 120
MAJOR MARKET DRIVERS AND RESTRAINTS 121
TABLE 85 GLOBAL IVD MARKET, THROUGH 2016 ($MILLIONS) 121
BREAST CANCER DRUG MARKET 121
BREAST CANCER TESTING MARKET 121
NEXT-GENERATION CANCER DIAGNOSTICS 122
TABLE 86 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, THROUGH 2016
($ MILLIONS) 122
FIGURE 13 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, 2010–2016 ($
MILLIONS) 122
GLOBAL MARKET AND TRENDS 123
TABLE 87 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010–2016 ($ THOUSANDS) 123
TABLE 88 GLOBAL INCIDENCE OF ESTROGEN RECEPTOR POSITIVE BRE
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |